



公告日期	2026/3/13
異動類別	藥品變更
異動原因	包裝變更
異動描述	Dupilumab inj 200mg/1.14mL/syringe (Dupixent [®])杜避炎因進行劑型變更，改以Dupilumab inj 200mg/1.14mL/pen (Dupixent [®])杜避炎替代。 舊品用罄，啟用新品。

異動內容		
	舊藥品	新藥品
料號	286755	
學名	Dupilumab	
商品名	Dupixent	
中文名	杜避炎 (2支/盒)	
主成份及含量	200mg/1.14mL/syringe	200mg/1.14mL/pen
製造廠名稱	Sanofi Winthrop Industrie (賽諾菲溫莎)	
產地	法國	
健保代碼	KC011332BL	
外觀/圖檔		
用法	皮下注射	

小孩劑量	Atopic dermatitis: (6 months ~ 5 years) 5 - < 15 kg: 200 mg SC once, followed by 200 mg SC Q4W. 15 - < 30 kg: 300 mg SC once, followed by 300 mg SC Q4W.
	Atopic dermatitis: (6 ~ 17 years) 15 - < 30 kg: 600 mg SC once, followed by 300 mg SC q4w. 30 - < 60 kg: 400 mg SC once, followed by 200 mg SC q2w. ? 60 kg: Refer to adult dosing.
	Asthma:(6 ~ 11 years) 15 - < 30 kg: 100 mg SC q2w or 300 mg Q4W ? 30 kg: 200 mg SC Q2W It is not recommended to give an initial loading dose.
	Asthma and co-morbid moderateto-severe atopic dermatitis:(6 ~ 11 years) Refer to 6 ~ 17 years atopic dermatitis dosing.
成人劑量	Atopic dermatitis: Initial: 600 mg SC once Maintenance: 300 mg SC Q2W
	Asthma (? 12 years) : Initial: 400 mg SC once Maintenance: 200 mg SC Q2W.
	Asthma, moderate to severe: Initial: 600 mg SC once Maintenance: 300 mg SC Q2W.
	Rhinosinusitis with nasal polyposis: 300 mg SC Q2W
副作用	